TY  - JOUR
AU  - Cavero, Teresa
AU  - Arjona, Emilia
AU  - Soto, Karina
AU  - Caravaca-Fontán, Fernando
AU  - Rabasco, Cristina
AU  - Bravo, Luis
AU  - de la Cerda, Francisco
AU  - Martín, Nadia
AU  - Blasco, Miquel
AU  - Ávila, Ana
AU  - Huerta, Ana
AU  - Cabello, Virginia
AU  - Jarque, Ana
AU  - Alcázar, Concepción
AU  - Fulladosa, Xavier
AU  - Carbayo, Javier
AU  - Anaya, Sara
AU  - Cobelo, Carmen
AU  - Ramos, Natalia
AU  - Iglesias, Elena
AU  - Baltar, José
AU  - Martínez-Gallardo, Rocío
AU  - Pérez, Lourdes
AU  - Morales, Enrique
AU  - González, Roberto
AU  - Macía, Manuel
AU  - Draibe, Juliana
AU  - Pallardó, Luis
AU  - Quintana, Luis F
AU  - Espinosa, Mario
AU  - Barros, Xoana
AU  - Pereira, Fernando
AU  - Cao, Mercedes
AU  - Moreno, Juan Antonio
AU  - Rodríguez de Córdoba, Santiago
AU  - Praga, Manuel
AU  - Spanish Group for the Study of Glomerular Diseases (GLOSEN)
PY  - 2019
DO  - 10.1016/j.kint.2019.05.014
UR  - http://hdl.handle.net/10668/14404
T2  - Kidney international
AB  - Malignant hypertension is listed among the causes of secondary thrombotic microangiopathy, but pathogenic mutations in complement genes have been reported in patients with hypertension-induced thrombotic microangiopathy. Here we investigated the...
LA  - en
KW  - atypical hemolytic uremic syndrome
KW  - complement
KW  - eculizumab
KW  - malignant hypertension
KW  - Adult
KW  - Antibodies, Monoclonal, Humanized
KW  - Atypical Hemolytic Uremic Syndrome
KW  - Complement Inactivating Agents
KW  - Complement System Proteins
KW  - Female
KW  - Humans
KW  - Hypertension, Malignant
KW  - Incidence
KW  - Male
KW  - Middle Aged
KW  - Plasmapheresis
KW  - Retrospective Studies
KW  - Severity of Illness Index
KW  - Young Adult
TI  - Severe and malignant hypertension are common in primary atypical hemolytic uremic syndrome.
TY  - research article
VL  - 96
ER  -